These acquired KRAS mutations include other common variants in KRAS that are seen across mutant KRAS-driven cancers, such as the G13D and G12V substitutions, as well as a novel mutation in residue 96 (KRASY96D) that are yet to be documented in the clinic (Tanaka et al., 2021). This evidence concerns the gene KRAS and cancer.